Waters and Rosetta Biosoftware Achieve Collaborative Milestone

Advancing Proteomics Research with Secure Protein Identifications MILFORD, Mass. & SEATTLE–Waters Corporation (NYSE:WAT – News) and Rosetta Biosoftware today announced that the Rosetta Elucidator® system has been enabled to mine Waters® UltraPerformance LC®/MSE, high-bandwidth, proteomics discovery data and integrate the Waters IDENTITYE® search engine for secure protein identifications. Both companies will showcase their integrated solution at the upcoming American Society for Mass Spectrometry (ASMS) conference, in Denver, Colorado, June 1-5, 2008. “The advanced data interrogation and visualization tools within the Elucidator system leverage Waters’ uniquely information-rich data format,” said Tim Riley, Vice President and Managing Director – Pharmaceutical Business Operations, Waters Division. “This integration of the Waters UPLC®/MSE data acquisition strategy with the Elucidator system’s ability to characterize complex protein mixtures creates a powerhouse solution for all our proteomics customers.” “This development has produced interoperability that benefits our mutual customers and is in line with our commitment to provide flexible and interoperable software platforms that empower our customers to choose the best technologies to achieve their research goals,” said Yelena Shevelenko, General Manager of Rosetta Biosoftware. About Waters Corporation (www.waters.com) Waters Corporation creates business advantage for laboratory-dependent organizations by delivering practical and sustainable innovation to enable significant advancements in such areas as healthcare delivery, environmental management, food safety, and water quality worldwide. Pioneering a connected portfolio of separations science, laboratory information management, mass spectrometry and thermal analysis, Waters technology breakthroughs and laboratory solutions provide an enduring platform for customer success. With revenue of $1.47 billion in 2007 and 5,000 employees, Waters is driving scientific discovery and operational excellence for customers worldwide. About the Rosetta Elucidator System The Elucidator system’s advanced data management capabilities allow users to effectively organize, search for, and retrieve raw and processed protein expression data. The application serves as a core integrator for proteomics research by working directly with select instrument APIs, sample annotation systems, and common protein ID search engines. In addition, it provides a suite of advanced statistical analysis and visualization tools for data mining and discovery of potential protein biomarkers and proteins that are differentially expressed among different phenotypes or drug treatments. The Elucidator system combines these data management and analysis capabilities with the flexibility of a highly customizable environment: users can incorporate organization-specific workflows into customized visual scripts that leverage Elucidator system statistical tools and customer-proprietary algorithms, as well as those available in the public domain. The Rosetta Elucidator system is designed to meet the needs of both large and small organizations. Additional information about the Rosetta Elucidator system can be found on the Rosetta Biosoftware Web site at www.rosettabio.com. For more information and a schedule of Rosetta’s ASMS conference events, visit www.rosettabio.com/company/events. About Rosetta Biosoftware (www.rosettabio.com) Rosetta Biosoftware, Seattle, Wash., is a leading provider of informatics solutions for life science research. Its comprehensive software solutions, including the Rosetta Resolver and Rosetta Elucidator systems, empower life scientists with advanced, scalable, and easy-to-use analysis platforms that accelerate discovery research. Rosetta Biosoftware is a business unit of Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck & Co., Inc. More information about Rosetta Biosoftware is available at www.rosettabio.com. Forward-Looking Statements This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Neither Rosetta Inpharmatics nor Merck & Co., Inc. undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect the business of Merck & Co., Inc. including, among others, the extent to which Rosetta Inpharmatics’ technology platform can be used in drug discovery programs, uncertainty of market acceptance of Rosetta Inpharmatics’ technologies, ability to compete against existing technologies, and those mentioned in the cautionary statements in Item 1 of Merck’s Form 10-K for the year ended Dec. 31, 2007, and in its periodic reports on Form 10-Q and Form 8-K (if any) which are incorporated by reference. Waters, UltraPerformance LC, and UPLC are trademarks of Waters Corporation. Rosetta Resolver and Elucidator are U.S. registered trademarks of Rosetta Inpharmatics LLC.

< | >